Dawoud, M., Abd El-Wahed, M., Gaber, I., El-Dien, M. (2021). Immunohistochemical Expression of Annexin A2 in Endometrial Carcinoma. The Egyptian Journal of Hospital Medicine, 83(1), 1134-1141. doi: 10.21608/ejhm.2021.160886
Marwa M. Dawoud; Moshira M. Abd El-Wahed; Ilaf M.A. Gaber; Marwa M. Serag El-Dien. "Immunohistochemical Expression of Annexin A2 in Endometrial Carcinoma". The Egyptian Journal of Hospital Medicine, 83, 1, 2021, 1134-1141. doi: 10.21608/ejhm.2021.160886
Dawoud, M., Abd El-Wahed, M., Gaber, I., El-Dien, M. (2021). 'Immunohistochemical Expression of Annexin A2 in Endometrial Carcinoma', The Egyptian Journal of Hospital Medicine, 83(1), pp. 1134-1141. doi: 10.21608/ejhm.2021.160886
Dawoud, M., Abd El-Wahed, M., Gaber, I., El-Dien, M. Immunohistochemical Expression of Annexin A2 in Endometrial Carcinoma. The Egyptian Journal of Hospital Medicine, 2021; 83(1): 1134-1141. doi: 10.21608/ejhm.2021.160886
Immunohistochemical Expression of Annexin A2 in Endometrial Carcinoma
Pathology Department, Faculty of Medicine, Menofia University, Egypt
Abstract
Background: Endometrial carcinoma (EC) is second common gynecological cancer worldwide. It represents 2.83% of female genital malignancy and 72.37% of uterine corpus malignancy according to Egyptian National Cancer Institute (NCI). Distinction between endometrial atypical hyperplasia (EAH) and EC has been controversial, with clinical impact. Objective: Investigate immunohistochemical expression of Annexin A2 (ANXA2) in EC versus endometrial proliferative lesions and correlation with available clinicopathological parameters. Materials and Methods: This retrospective study included formalin-fixed, paraffin-embedded blocks of 66 specimens of endometrial tissue divided into four groups: EC, EAH, endometrial hyperplasia (EH) without atypia and proliferative endometrium. Immunohistochemical staining by ANXA2 antibody was done. Evaluation by semi- quantitative scores followed by correlation of results with clinicopathological data was applied. Results: Annexin A2 was positive in all cases without significant variations between groups. Analysis using ROC curve revealed that immunohistochemical expression of ANXA2 has weak power in differentiating type I- EC from EAH. Correlation between ANXA2 expression and clinicopathological parameters in type I- EC showed a significant negative association between ANXA2 immuno-reactivity score (IRS) and maximum tumor dimension (P=0.03). On other hand, in type II- EC, there was a significant positive linear correlation between ANXA2 H-score and both maximum tumor dimension (P= 0.02) and apoptotic count (P=0.008). Conclusion: Annexin A2 is essential for development of endometrial tissue beside carrying good features in type I- EC by its association with small tumor size. In type II- EC, ANXA2 has two opposing effects; increased tumor maximum dimension and apoptosis. Net result is in favor of increase tumor burden.